Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
No Thumbnail Available
Identifiers
Date
2016-12-01
Authors
Fernandez-Mateos, J.
Seijas-Tamayo, R.
Mesia, R.
Taberna, M.
Pastor Borgonon, M.
Perez-Ruiz, E.
Klain, J. C. Adansa
Vazquez Fernandez, S.
del Barco Morillo, E.
Lozano, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science bv
Metrics
Export
Abstract
Objectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Head and neck squamous cell carcinoma (HNSCC), Epidermal growth factor receptor (EGFR), Polymorphism, SNP, EGFR, CCDN1, FCGR2A, FCGR3A, KRAS-LCS6, Cetuximab, Toxicity, Platinum-based chemotherapy, Phase-ii, Plus cetuximab, Skin toxicity, Single-agent, Lung-cancer, Open-label, Risk, Epidemiology, Combination